A prospective, open labeled, flexible-dose and 4-8 week design study for the efficacy and tolerability of aripiprazole for treating patients who were previously treated but who had an inadequate response to their current delayed sleep phase syndrome and hypersomnolence disorder.

A prospective, open labeled, flexible-dose and 4-8 week design study for the efficacy and tolerability of aripiprazole for treating patients who were previously treated but who had an inadequate response to their current delayed sleep phase syndrome and hypersomnolence disorder. - Aripiprazole for treating patients with delayed sleep phase syndrome and hypersomnolence disorder.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029268

Enrollment

Registered

2017-10-01

Start date

2016-09-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delayed sleep phase syndrome and hypersomnolence disorder.

Interventions

Study period: 4-8 weeks, amount of medication: aripiprazole 0.5-3mg/day, once a day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who were delayed sleep phase syndrome or hypersomnolence disorders.

Exclusion criteria

Exclusion criteria: Patients who do not obtain consent.

Design outcomes

Primary

Measure	Time frame
Total sleep time at 1-2-4 weeks.	—

Secondary

Measure	Time frame
Side effects at 1-2-4 weeks.	—

Countries

Japan

Contacts

Public ContactYuki Omori

Akita University Graduate School of Medicine, Akita, Japan. Department of Neuropsychiatry

oyu-d612@med.akita-u.ac.jp018-884-6122

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026